|
Market Cap | 3.61B | EPS (ttm) | 2.73 |
P/E | 7.92 | EPS this Y | -21.73% |
Forward P/E | 7.04 | EPS next Y | 23.69% |
PEG | - | EPS past 5Y | 11.79% |
P/S | 0.79 | EPS next 5Y | -1.00% |
P/B | 1.90 | EPS Q/Q | -46.82% |
Dividend | 1.42% | Sales Q/Q | -14.97% |
Insider Own | 3.68% | Inst Own | 99.49% |
Insider Trans | -7.98% | Inst Trans | -7.19% |
Short Float | 10.20% | Earnings | Apr 17/a |
Analyst Recom | 2.06 | Target Price | 25.21 |
Avg Volume | 2.72M | 52W Range | 11.62 - 23.31 |
|
|
|
Liberty Energy, Inc. engages in the provision of hydraulic fracturing services to onshore oil and natural gas exploration for production companies in North America. The company was founded on December 21, 2016 and is headquartered in Denver, CO. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Wright Christopher A | Chairman of the Board and CEO | May 03 '24 | Sale | 21.64 | 20,000 | 432,800 | 2,818,814 | May 03 07:50 PM | Wright Christopher A | Chairman of the Board and CEO | May 02 '24 | Sale | 21.39 | 20,000 | 427,800 | 2,838,814 | May 03 07:50 PM | Stock Michael | Chief Financial Officer | May 01 '24 | Sale | 21.83 | 20,000 | 436,596 | 825,209 | May 01 04:29 PM | Gusek Ron | President | Apr 30 '24 | Sale | 22.70 | 42,397 | 962,539 | 1,170,862 | Apr 30 04:36 PM | Gusek Ron | President | Apr 29 '24 | Sale | 22.99 | 50,000 | 1,149,470 | 1,213,259 | Apr 30 04:36 PM |
|
|
|
|
Market Cap | 192.89B | EPS (ttm) | 7.35 |
P/E | 22.40 | EPS this Y | 30.93% |
Forward P/E | 14.69 | EPS next Y | 23.49% |
PEG | 0.88 | EPS past 5Y | 15.59% |
P/S | 2.46 | EPS next 5Y | 25.48% |
P/B | 3.12 | EPS Q/Q | 26.03% |
Dividend | 1.61% | Sales Q/Q | -0.19% |
Insider Own | 62.74% | Inst Own | 38.84% |
Insider Trans | -2.24% | Inst Trans | -1.03% |
Short Float | 5.31% | Earnings | Apr 25/a |
Analyst Recom | 1.52 | Target Price | 188.49 |
Avg Volume | 4.33M | 52W Range | 124.92 - 168.64 |
|
|
|
T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
DEUTSCHE TELEKOM AG | Director | May 03 '24 | Sale | 164.63 | 189,670 | 31,225,521 | 677,158,691 | May 03 07:50 PM | DEUTSCHE TELEKOM AG | Director | May 02 '24 | Sale | 165.02 | 189,670 | 31,299,321 | 677,348,361 | May 03 07:50 PM | DEUTSCHE TELEKOM AG | Director | May 01 '24 | Sale | 165.67 | 189,670 | 31,423,286 | 677,538,031 | May 03 07:50 PM | DEUTSCHE TELEKOM AG | Director | Apr 30 '24 | Sale | 163.76 | 189,670 | 31,059,839 | 677,727,701 | Apr 30 07:38 PM | DEUTSCHE TELEKOM AG | Director | Apr 29 '24 | Sale | 164.15 | 189,670 | 31,134,333 | 677,917,371 | Apr 30 07:38 PM |
|
|
|
|
Market Cap | 166.83B | EPS (ttm) | 6.99 |
P/E | 44.51 | EPS this Y | 4.61% |
Forward P/E | 15.05 | EPS next Y | 6.01% |
PEG | 8.49 | EPS past 5Y | -0.22% |
P/S | 5.68 | EPS next 5Y | 5.25% |
P/B | 33.25 | EPS Q/Q | -103.99% |
Dividend | 2.99% | Sales Q/Q | 22.19% |
Insider Own | 0.24% | Inst Own | 78.10% |
Insider Trans | -1.09% | Inst Trans | -1.47% |
Short Float | 1.89% | Earnings | May 02/a |
Analyst Recom | 2.13 | Target Price | 313.89 |
Avg Volume | 2.93M | 52W Range | 211.71 - 329.72 |
|
|
May-03-24 | Upgrade |
William Blair |
Mkt Perform → Outperform |
|
May-03-24 | Upgrade |
Barclays |
Underweight → Equal Weight |
$230 → $300 |
|
Today 01:03AM
|
Decoding Amgen Inc (AMGN): A Strategic SWOT Insight
(GuruFocus.com) |
May-03-24 06:15PM
|
Why Amgen Stock Zoomed Nearly 12% Higher Today
(Motley Fool) +11.82% |
05:07PM
|
Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
(Yahoo Finance) |
04:51PM
|
These Stocks Moved the Most Today: Apple, Amgen, Expedia, Coinbase, Cloudflare, Fortinet, Live Nation, and More
(Barrons.com) |
04:49PM
|
S&P 500 Gains and Losses Today: Amgen Soars as Weight-Loss Drug Shows Promise
(Investopedia) |
04:04PM
|
Amgen Is 'Very Encouraged' With Its Obesity Drug. But Can It Take On Novo, Lilly Duopoly?
(Investor's Business Daily) |
03:46PM
|
These Stocks Are Moving the Most Today: Apple, Amgen, Expedia, Coinbase, Cloudflare, Fortinet, Live Nation, and More
(Barrons.com) |
02:53PM
|
Analyst unveils Amgen stock price target after weight-loss drug data
(TheStreet) |
01:58PM
|
Sector Update: Health Care Stocks Mixed in Afternoon Trading
(MT Newswires) |
01:00PM
|
Interest rate cuts could switch from stroll to a sprint after US jobs surprise
(The Telegraph) |
|
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Grygiel Nancy A. | SVP & CCO | May 03 '24 | Sale | 313.09 | 2,117 | 662,802 | 9,883 | May 03 07:48 PM | Grygiel Nancy A. | SVP & CCO | Dec 04 '23 | Sale | 273.03 | 2,096 | 572,276 | 10,874 | Dec 04 07:41 PM | Graham Jonathan P | EVP, Gen. Counsel & Secy. | Nov 08 '23 | Sale | 272.81 | 10,000 | 2,728,136 | 28,078 | Nov 13 08:30 PM | AMGEN INC | 10% Owner | Sep 19 '23 | Buy | 17.00 | 1,764,705 | 29,999,985 | 35,368,653 | Sep 19 07:52 PM | Gordon Murdo | EVP, Global Commercial Ops | Aug 10 '23 | Sale | 262.43 | 9,558 | 2,508,306 | 44,308 | Aug 11 06:13 PM |
|
|
| |
|
Market Cap | 10.29B | EPS (ttm) | 0.32 |
P/E | 743.03 | EPS this Y | 253.53% |
Forward P/E | 102.83 | EPS next Y | 88.62% |
PEG | 21.66 | EPS past 5Y | - |
P/S | 19.38 | EPS next 5Y | 34.30% |
P/B | 15.57 | EPS Q/Q | 171.66% |
Dividend | - | Sales Q/Q | 45.42% |
Insider Own | 15.93% | Inst Own | 77.13% |
Insider Trans | -6.91% | Inst Trans | -0.10% |
Short Float | 4.98% | Earnings | May 08/a |
Analyst Recom | 2.12 | Target Price | 252.19 |
Avg Volume | 773.79K | 52W Range | 116.82 - 245.87 |
|
|
|
Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Skaruppa Matthew | Chief Financial Officer | May 01 '24 | Option Exercise | 14.42 | 8,000 | 115,360 | 72,523 | May 03 07:38 PM | von Ahn Luis | President & CEO, Co-Founder | May 01 '24 | Sale | 223.51 | 12,000 | 2,682,139 | 0 | May 03 07:37 PM | Hacker Severin | Chief Tech Officer, Co-Founder | May 01 '24 | Sale | 223.47 | 10,000 | 2,234,653 | 0 | May 03 07:39 PM | Skaruppa Matthew | Chief Financial Officer | May 01 '24 | Sale | 223.46 | 8,000 | 1,787,708 | 64,523 | May 03 07:38 PM | Glance Natalie | Chief Engineering Officer | Apr 08 '24 | Sale | 215.35 | 1,500 | 323,025 | 124,505 | Apr 09 04:16 PM |
|
|
|
|
Market Cap | 6.85B | EPS (ttm) | -3.77 |
P/E | - | EPS this Y | 17.83% |
Forward P/E | - | EPS next Y | -7.55% |
PEG | - | EPS past 5Y | -36.05% |
P/S | 591.86 | EPS next 5Y | - |
P/B | 3.62 | EPS Q/Q | -80.53% |
Dividend | - | Sales Q/Q | -95.16% |
Insider Own | 17.12% | Inst Own | 76.44% |
Insider Trans | -0.50% | Inst Trans | 8.22% |
Short Float | 8.84% | Earnings | May 08/a |
Analyst Recom | 1.07 | Target Price | 41.62 |
Avg Volume | 1.50M | 52W Range | 15.44 - 39.60 |
|
|
|
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Anders Jack | Chief Financial Officer | May 03 '24 | Option Exercise | 2.68 | 10,000 | 26,800 | 111,959 | May 03 07:36 PM | Anders Jack | Chief Financial Officer | May 03 '24 | Sale | 40.03 | 10,000 | 400,260 | 101,959 | May 03 07:36 PM | Patel Sushil | Director | Apr 10 '24 | Option Exercise | 16.80 | 2,155 | 36,204 | 17,855 | Apr 12 04:23 PM | GOLDSMITH MARK A | See Remarks | Apr 10 '24 | Sale | 35.33 | 10,000 | 353,346 | 30,424 | Apr 12 08:08 PM | GOLDSMITH MARK A | See Remarks | Apr 10 '24 | Sale | 35.48 | 7,500 | 266,122 | 452,879 | Apr 12 08:08 PM |
|
|
| |
|
Market Cap | 4.78B | EPS (ttm) | 1.97 |
P/E | 47.88 | EPS this Y | -0.45% |
Forward P/E | 46.19 | EPS next Y | 5.74% |
PEG | 3.19 | EPS past 5Y | 7.81% |
P/S | 8.83 | EPS next 5Y | 15.00% |
P/B | 13.40 | EPS Q/Q | 4.70% |
Dividend | 1.19% | Sales Q/Q | 3.30% |
Insider Own | 1.48% | Inst Own | 93.47% |
Insider Trans | -2.34% | Inst Trans | -0.42% |
Short Float | 2.87% | Earnings | Apr 25/a |
Analyst Recom | 2.33 | Target Price | 94.00 |
Avg Volume | 290.77K | 52W Range | 64.61 - 102.72 |
|
|
|
Exponent, Inc. is an engineering and scientific consulting company, which provides engineering, scientific, environmental, and health consulting services. It operates through the Engineering and Other Scientific, and Environmental and Health segments. The Engineering and Other Scientific segment includes technical consulting in different practices primarily in engineering. The Environmental and Health segment offers services in environmental, epidemiology, and health risk analysis. The company was founded by Bernard Ross in 1967 and is headquartered in Menlo Park, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
James Bradley A | Group Vice President | May 03 '24 | Sale | 93.77 | 5,545 | 519,958 | 5,558 | May 03 07:34 PM | James Bradley A | Group Vice President | May 02 '24 | Sale | 93.00 | 13 | 1,209 | 11,103 | May 03 07:34 PM | Guyer Eric | Group Vice Presient | Apr 30 '24 | Sale | 92.58 | 1,650 | 152,762 | 1,846 | Apr 30 08:57 PM | Guyer Eric | Group Vice Presient | Feb 09 '24 | Sale | 78.49 | 3,367 | 264,289 | 0 | Feb 09 04:18 PM | SCHLENKER RICHARD L JR | EVP & Chief Financial Officer | Feb 06 '24 | Option Exercise | 17.70 | 5,648 | 99,970 | 288,990 | Feb 08 03:00 PM |
|
|
|
|
Market Cap | 592.27M | EPS (ttm) | 0.84 |
P/E | 38.28 | EPS this Y | 94.04% |
Forward P/E | - | EPS next Y | -3980.68% |
PEG | - | EPS past 5Y | 12.62% |
P/S | 167.31 | EPS next 5Y | - |
P/B | 3.44 | EPS Q/Q | 104.08% |
Dividend | - | Sales Q/Q | 119.90% |
Insider Own | 3.49% | Inst Own | 87.94% |
Insider Trans | 12.78% | Inst Trans | 5.05% |
Short Float | 5.85% | Earnings | Feb 14/a |
Analyst Recom | 1.50 | Target Price | 70.25 |
Avg Volume | 120.65K | 52W Range | 27.20 - 40.45 |
|
|
|
Anterix, Inc. engages in commercializing spectrum assets to enable targeted utility and critical infrastructure customers to deploy private broadband networks, technologies and solutions. Its solutions include Private LTE and Active Ecosystem. The company was founded by Peter Joel Lasensky and Richard Edward Rohmann in 1997 and is headquartered in Woodland Park, NJ. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Gray Timothy | Chief Financial Officer | May 03 '24 | Option Exercise | 20.00 | 16,666 | 333,320 | 107,141 | May 03 07:34 PM | Gray Timothy | Chief Financial Officer | May 03 '24 | Sale | 32.26 | 16,666 | 537,645 | 90,475 | May 03 07:34 PM | Gray Timothy | Chief Financial Officer | May 02 '24 | Option Exercise | 20.00 | 16,667 | 333,340 | 107,142 | May 03 07:34 PM | Gray Timothy | Chief Financial Officer | May 02 '24 | Sale | 31.91 | 16,667 | 531,844 | 90,475 | May 03 07:34 PM | Gray Timothy | Chief Financial Officer | May 01 '24 | Option Exercise | 20.00 | 16,667 | 333,340 | 107,142 | May 03 07:34 PM |
|
|
| |
|
Market Cap | 1.22B | EPS (ttm) | -0.69 |
P/E | - | EPS this Y | -192.59% |
Forward P/E | - | EPS next Y | 74.05% |
PEG | - | EPS past 5Y | 19.36% |
P/S | - | EPS next 5Y | - |
P/B | 5.06 | EPS Q/Q | -27.40% |
Dividend | - | Sales Q/Q | -100.00% |
Insider Own | 22.62% | Inst Own | 63.99% |
Insider Trans | 0.70% | Inst Trans | 43.43% |
Short Float | 10.12% | Earnings | May 09/b |
Analyst Recom | 1.00 | Target Price | 34.29 |
Avg Volume | 448.20K | 52W Range | 11.83 - 23.81 |
|
|
|
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Rickard Kathleen A. | Chief Medical Officer | May 03 '24 | Sale | 1.96 | 36,248 | 71,032 | 2,621,552 | May 03 07:21 PM | Rickard Kathleen A. | Chief Medical Officer | Feb 05 '24 | Sale | 2.22 | 36,248 | 80,503 | 2,731,624 | Feb 05 06:11 PM | Edwards Martin | Director | Nov 20 '23 | Buy | 1.84 | 33,736 | 61,973 | 144,800 | Nov 22 05:09 PM | EBSWORTH DAVID R | Director | Nov 06 '23 | Buy | 1.98 | 160,000 | 316,080 | 844,643 | Nov 08 04:15 PM | Rickard Kathleen A. | Chief Medical Officer | Nov 03 '23 | Sale | 1.92 | 58,752 | 112,804 | 2,840,640 | Nov 03 08:11 PM |
|
|
|
|
Market Cap | 15.70B | EPS (ttm) | -0.60 |
P/E | - | EPS this Y | 148.59% |
Forward P/E | 43.95 | EPS next Y | 37.79% |
PEG | - | EPS past 5Y | -48.35% |
P/S | 8.31 | EPS next 5Y | - |
P/B | 2.34 | EPS Q/Q | 118.21% |
Dividend | - | Sales Q/Q | 24.61% |
Insider Own | 49.49% | Inst Own | 38.57% |
Insider Trans | -0.84% | Inst Trans | 4.24% |
Short Float | 7.13% | Earnings | May 08/a |
Analyst Recom | 2.89 | Target Price | 19.20 |
Avg Volume | 15.79M | 52W Range | 7.91 - 20.55 |
|
|
|
Robinhood Markets, Inc is a financial services platform that pioneered commission-free stock trading with no account minimums and fractional share trading. The firm is focused on providing retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Tenev Vladimir | Chief Executive Officer | May 02 '24 | Sale | 17.04 | 25,049 | 426,875 | 32,584 | May 03 07:19 PM | Warnick Jason | Chief Financial Officer | May 01 '24 | Sale | 16.72 | 5,000 | 83,602 | 997,407 | May 03 07:14 PM | Bhatt Baiju | Director | Apr 23 '24 | Sale | 17.61 | 154,160 | 2,714,835 | 0 | Apr 25 06:46 PM | Bhatt Baiju | Director | Apr 18 '24 | Sale | 17.16 | 16,667 | 285,994 | 0 | Apr 22 06:42 PM | Tenev Vladimir | Chief Executive Officer | Apr 04 '24 | Sale | 18.67 | 250,000 | 4,668,675 | 0 | Apr 08 06:40 PM |
|
|
|
|
Market Cap | 676.69M | EPS (ttm) | -3.04 |
P/E | - | EPS this Y | 3.21% |
Forward P/E | - | EPS next Y | -16.48% |
PEG | - | EPS past 5Y | -241.80% |
P/S | - | EPS next 5Y | - |
P/B | 2.44 | EPS Q/Q | -38.12% |
Dividend | - | Sales Q/Q | - |
Insider Own | 64.61% | Inst Own | 28.92% |
Insider Trans | -0.46% | Inst Trans | -0.53% |
Short Float | 2.83% | Earnings | Mar 20/a |
Analyst Recom | 1.00 | Target Price | 29.25 |
Avg Volume | 158.57K | 52W Range | 9.94 - 20.22 |
|
|
|
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Kohli Aditya | Director | May 03 '24 | Sale | 14.15 | 723 | 10,233 | 782,878 | May 03 07:12 PM | Kohli Aditya | Director | May 02 '24 | Sale | 14.01 | 6,000 | 84,081 | 783,601 | May 03 07:12 PM | Kohli Aditya | Director | May 01 '24 | Sale | 14.03 | 175 | 2,456 | 789,601 | May 03 07:12 PM | Kohli Aditya | Director | Apr 05 '24 | Sale | 14.44 | 6,000 | 86,640 | 789,776 | Apr 05 05:48 PM | Frazier Life Sciences X, L.P. | 10% Owner | Apr 04 '24 | Buy | 14.50 | 8,850 | 128,325 | 8,544,187 | Apr 08 04:22 PM |
|
|
|